HPCSA-registeredSAHPRA-authorisedPOPIA-secure

DOCTO24
Sign inCHECK ELIGIBILITY

Patient guide

Section 21 cannabis in South Africa — the complete patient guide

Last updated · Published

Everything a South African patient needs to know about legal medical cannabis access under SAHPRA Section 21 — eligibility, process, cost, rights, misconceptions, and the law itself. Read this end-to-end if you are considering medical cannabis for the first time, or jump to the section that matters to you.

1. What is Section 21?

Section 21 of the Medicines and Related Substances Act 101 of 1965 is the legal mechanism that lets SAHPRA — the South African Health Products Regulatory Authority — authorise access to medicines that are not formally registered for general sale in South Africa.

In practice, this is how the vast majority of medical cannabis products are accessed legally in SA. Each authorisation is issued for a specific patient, a specific product, and a specific time window (typically six months). It is not a blanket approval of cannabis — it is a case-by-case clinical decision, reviewed by SAHPRA, filed by an HPCSA-registered doctor who has assessed the patient.

2. Schedule 0 CBD vs Section 21 medical cannabis

This is the single most confused distinction in South African cannabis law. There are two different legal pathways and they serve different purposes:

  • Schedule 0 (over-the-counter) CBD — under Gazette 43347, low-dose CBD products (≤600 mg per pack, ≤20 mg per dose) are sold OTC for general-health claims only. No disease-specific therapeutic framing is permitted.
  • Section 21 medical cannabis — for clinically relevant doses, therapeutic indications, and THC-containing products. These require a doctor’s prescription, SAHPRA’s authorisation, and pharmacy dispensing.

If you see a commercial product claiming to treat epilepsy, anxiety, or cancer outside the Section 21 pathway, it is either non-compliant or operating on hope rather than evidence. The legal — and clinically responsible — route for those indications is Section 21.

3. Who is eligible?

Eligibility is decided case-by-case by an HPCSA-registered doctor, based on your full clinical picture. The common thread is that conventional first-line therapy has been tried and has not delivered adequate benefit or has caused intolerable side effects. Indications we most commonly evaluate:

Inclusion on this list is not a guarantee of approval. Some conditions with a stronger evidence base (MS spasticity, refractory epilepsy, neuropathic pain) are approved more frequently; others require more thorough documentation.

4. The application process

The clinical process is the same regardless of condition. It is documented in full on our how-it-works page, but at a glance:

  1. Sign up — create a secure account with your email.
  2. Complete the clinical assessment — your history, current medications, and supporting records (specialist letters, prior treatments).
  3. Doctor review — an HPCSA-registered doctor reviews asynchronously or schedules a short video consult.
  4. SAHPRA filing — the doctor files a Named Patient Application for each product.
  5. Pharmacy dispense — once approved, your chosen partner pharmacy dispenses and courier-delivers anywhere in SA.

5. What does it cost?

There are no Docto24 subscription fees or membership costs. The real costs are:

  • Doctor consultation — typically R500 per case.
  • SAHPRA Section 21 fee — R400 per product, paid to SAHPRA via the application.
  • Medication + delivery — priced by the dispensing pharmacy, shown before you confirm.

Full breakdown on the pricing page.

6. Your rights as a patient

The POPIA (Protection of Personal Information Act) gives you a set of rights over your health data. Key ones you should know about:

  • Access your records — you can export your full data bundle via the DSAR process under POPIA §23.
  • Breach notification — if our records are compromised, we are obliged to notify you and the Information Regulator (POPIA §22).
  • Retention windows — HPCSA requires 6-year retention of medical records; ancillary data (IP, device metadata) is purged on faster cycles.
  • HPCSA complaint channels — if you have a concern about a doctor’s conduct, the HPCSA maintains a formal complaint process.

7. Common misconceptions

  • “Cannabis is decriminalised, so I can just buy it.” Private adult use and cultivation are decriminalised. That is not the same as a legal commercial supply chain for prescription-grade medicine. Section 21 remains the only regulated pathway for medical cannabis.
  • “The doctor just signs off — it is a formality.” The doctor exercises independent clinical judgement. Section 21 approvals are not rubber-stamped; applications are declined regularly when clinical indication is unclear or first-line therapy has not been documented.
  • “CBD oil I buy online is the same as Section 21.” It is not. Schedule 0 OTC CBD is limited in dose and restricted to general-health claims. Therapeutic-level dosing is a different product and a different legal track.
  • “Cannabis cures cancer.” It does not. Cannabinoids are used as symptomatic support alongside oncology care — for pain, nausea, appetite loss. Any provider framing it as anti-tumour therapy is giving unsafe, non-evidence-based advice.

8. Timeline: what to expect

End-to-end, from first sign-up to first dispense, most patients experience something like this:

  • Day 0: assessment submitted.
  • Day 0–1: doctor review; case accepted or further info requested.
  • Day 1–2: SAHPRA Section 21 application filed.
  • Day 3–5: SAHPRA authorisation issued (typical).
  • Day 4–7: pharmacy dispenses; courier delivery lands.

Delays can happen — incomplete documentation, SAHPRA queue depth, pharmacy stock. The live status is always visible in your dashboard.

9. Frequently asked questions

Is cannabis legal in South Africa?
Medical cannabis accessed via a SAHPRA Section 21 authorisation and dispensed by a licensed pharmacy is fully legal. Private adult cultivation and private adult use are decriminalised under the Constitutional Court ruling and the Cannabis for Private Purposes Act (2024), but private-use cannabis is not a lawful supply chain for prescription-quality medicine. Docto24 operates exclusively within the regulated Section 21 pathway.
How long does Section 21 approval take?
SAHPRA typically issues Section 21 authorisations within 2 to 3 business days of a complete submission. Docto24’s role is to file the application correctly the first time — we do not control SAHPRA’s queue.
Who can prescribe medical cannabis in South Africa?
Only HPCSA-registered medical practitioners. There is no separate cannabis-specific licence. Prescribing doctors apply to SAHPRA under Section 21 on a per-patient, per-product basis.
Can I grow cannabis at home and use that medically?
No. Private-use cannabis grown under the Cannabis for Private Purposes Act is not a regulated medicine. It has no standardised cannabinoid content, no batch testing, and no pharmacy dispense chain-of-custody. Medical use requires a Section 21 authorisation and dispense by a licensed pharmacy.
Do I need medical aid to access this?
No. Medical aid may cover the consultation under code 0130 depending on scheme rules, but the Section 21 fee and the dispensed medication are typically self-funded. Check your scheme before you book.
How is this different from buying CBD oil online?
Low-dose CBD (≤600 mg per pack, ≤20 mg per dose) is available over-the-counter under Schedule 0 for general-health claims only — no disease-specific therapeutic framing. Clinically relevant doses for epilepsy, anxiety, or chronic-pain indications sit outside that carve-out and require Section 21 access under specialist oversight.
What happens if my application is declined?
SAHPRA can request more information or decline the application. If declined, your doctor explains the reason and discusses alternatives — often additional documentation, a different formulation, or a different clinical pathway. A decline is not a permanent barrier.
Can I travel with Section 21-prescribed cannabis?
Within South Africa — yes, with your prescription and dispensing documentation. Across borders — generally no. Section 21 authorisations do not extend beyond SA; destination countries have their own rules. Consult the embassy of the country you are travelling to before departure.
What records are kept about my treatment?
HPCSA-mandated medical records are retained for 6 years after the last consultation, consistent with national medical-record retention rules. SAHPRA receives your application details but not your broader medical history. All data is POPIA-aligned — see our privacy notice.
Can the Section 21 authorisation be renewed?
Yes. Authorisations are valid for 6 months and can be renewed where continued clinical need is documented. Renewal involves a review of treatment outcomes and adjusted clinical reasoning; it is not automatic.

10. What the law actually says

We frame all content against the specific statutes that govern medical cannabis in South Africa. Where relevant, here are the primary references:

  • Medicines and Related Substances Act 101 of 1965, particularly §21 (access to unregistered medicines), §22A (prescription rules), and §18C (restrictions on advertising prescription medicines to the public).
  • HPCSA Rule 27 — ethical rules for advertising by medical practitioners; forbids therapeutic claims and comparative testimonials.
  • Cannabis for Private Purposes Act (2024) — governs adult private use and cultivation; distinct from the medical pathway.
  • Protection of Personal Information Act (POPIA, 2013) — data-subject rights, breach notification, retention rules.
  • Gazette 43347 (May 2020) — the Schedule 0 CBD carve-out under conditions.

This page is a patient-oriented summary, not legal advice. For legal interpretation, consult a South African attorney.

Think this pathway might apply to you? An HPCSA-registered doctor will review your case — no commitment until you confirm the consultation.

START ELIGIBILITY REVIEW